Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250022/S009

Volt PFA Catheter, Sensor Enabled

ABBOTT MEDICAL · Decision date Oct 8, 2026

MEDTECHLEDGER EXPLANATIONP250022/S009

What did the FDA decide?

FDA posted a 30-Day Notice for supplement S009 to PMA P250022 for the Volt PFA Catheter, Sensor Enabled, from Abbott Medical. The decision date is October 8, 2026, with decision code OK30. The stated purpose is minor dimensional tolerance changes on a catheter component.

The supplement type is a process change involving manufacturer, sterilizer, packager, or supplier. The device category is a percutaneous cardiac ablation catheter for treatment of atrial fibrillation with irreversible electroporation. The source statement does not specify which component changed, the magnitude of tolerance adjustment, or any associated testing. A supplement is not a new approval of the whole system.

FDA approval order statement

for minor dimensional tolerance changes on catheter component
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 8, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250022/S009
Regulatory pathway
PMA supplement
Product code
QZI
Decision code
OK30
Decision date
Oct 8, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

For the original device and its historical approval scope, see PMA P250022. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250022/S009 received

    Application receipt date recorded by FDA.

  2. P250022/S012 · Related supplement

    VOLT PFA CATHETER, SENSOR ENABLED

  3. P250022/S009 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P250022. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250022

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA approvalDec 19, 2025FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA
Medtronic, Inc.PMA supplementOct 6, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
5050 Nathan Ln. N., Plymouth, MN, 55442

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records